'Rapidly changing macro-environment' prompts Baxter split

By Gayle S. Putrich
Staff Reporter

Published: April 1, 2014 11:23 am ET
Updated: April 1, 2014 11:42 am ET

Related to this story

Topics Medical Medical/Pharmaceutical
Companies & Associations

Macroeconomics and market forces were the drivers behind the impending break-up of medical products manufacturer Baxter International Inc., company officials and analysts say, particularly in the medical device business.

The medical devices business tends to be somewhat defensive and slow growing in nature, while the biopharmaceuticals division carries more risk in growth and while both are medical, the two sides of the business have become so distinct that splitting them up made sense, company officials explained.

“Separating these businesses will enhance value for all our constituents including shareholders, patients, healthcare professionals and providers and employees. These businesses operate in distinct markets with evolving underlying fundamentals,” said Baxter spokeswoman Deborah Spak.

Longtime Baxter CEO Robert Parkinson, Jr. will lead the medical products side, which will retain the Baxer name, while Ludwig Hantson, president of the company's BioScience unit, will become the CEO of the biopharmaceuticals company. Both companies will continue to be based in northern Illinois after the split is complete, sometime in mid-2015.

“Baxter has an established history of executing successful spinoffs, and we have continued to evaluate the separation of these two businesses in response to diverging business dynamics and the rapidly changing macro-environment,” Parkinson said in a statement. “This decision underscores Baxter's commitment to ensuring its long-term strategic priorities remain aligned with shareholders' best interests, while improving our competitive position and performance, enhancing operational, commercial and scientific effectiveness and creating value for patients, healthcare providers and other key stakeholders.”

Baxter’s spinoff history includes the 2000 breakout of its cardiovascular business, which became Edwards Lifesciences, known for its artificial heart valves.

The global medical device industry has experienced significant growth over the last five years and analysts continue to have bullish expectations, projecting device sales to grow to more than $300 billion in the United States by 2017.

Baxter’s medical products business saw 2013 sales of more than $9 billion, with a product portfolio that includes drug delivery systems and administration sets, premixed and other injectable drugs, as well as inhalation anesthetics and hospital-based biosurgery products.  The division got a boost with the 2012 acquisition of Gambro AB, a Swedish dialysis market leader, which Spak said is still being integrated into Baxter.

“As a standalone company with greater management focus, Medical Products will be better positioned to realize the benefits from the long-term opportunities and significant commercial and cost synergies Gambro provides,” Sprak said.

Baxter said its biotech business, best known for its products to treat hemophilia and other bleeding disorders, had 2013 revenue of $6 billion.

The day after the announcement, three major ratings agencies downgraded the company following the announcement, though its stock soared by nearly 10 percent for a 52-week high.

Standard & Poor’s Ratings Services downgraded corporate credit and unsecured debt ratings on Deerfield-based Baxter to “A-" from “A” and placed the ratings on watch “with negative implications.” Moody’s Investors Services changed its outlook to negative from stable, and Fitch Ratings placed five long- and short-term ratings on "negative watch" while saying "the split makes strategic sense as the two business segments generally service different end markets.”

The Baxter split is similar to a move made last year by Abbot Laboratories, which spun off its drug business into a new company, AbbVie Inc. Abbott's remaining business focuses on implantables, diagnostic devices and generic drugs.


Comments

'Rapidly changing macro-environment' prompts Baxter split

By Gayle S. Putrich
Staff Reporter

Published: April 1, 2014 11:23 am ET
Updated: April 1, 2014 11:42 am ET

Post Your Comments


Back to story


More stories

Image

Coloplast doubles size of Hungarian medical products plant

April 27, 2015 9:35 am ET

Danish medical care products manufacturer Coloplast A/S has doubled the size of the Nyírbátor production plant, one of two units it operates in...    More

Market Reports

North American Thermoformed Packaging Market Outlook & Review 2015

Our annual report provides a thorough review and analysis of economic and political conditions, emerging market trends, packaging design advances, materials pricing and sustainable packaging issues impacting supply and demand in the TP segment. Our analysts identify key drivers of growth and opportunities for processors to remain competitive in the years ahead through innovation, production efficiencies and more.

Learn more

Plastics Recycling Trends in North America

This report is a review and analysis of the North American Plastics Recycling Industry, including key trends and statistics based on 2013 performance. We examine market environment factors, regulatory issues, industry challenges, key drivers and emerging trends in post-consumer and post-industrial recycling.

Learn more

Plastics Caps & Closures Market Report

The annual recap of top trends and future outlook for the plastics caps & closures market features interviews with industry thought leaders and Bill Wood’s economic forecast of trends in growing end markets. You will also gain insight on trends in caps design, materials, machinery, molds & tooling and reviews of mergers & acquisitions.

Learn more

Upcoming Plastics News Events

June 2, 2015 - June 3, 2015Plastics Financial Summit - Chicago 2015

September 15, 2015 - September 17, 2015Plastics Caps & Closures - September 2015

More Events